STOCKS TELEGRAPH

Tag: T2 Biosystems Inc.

  • Q2 Results Spark Post-Market Rally For T2 Biosystems (TTOO) Shares

    Q2 Results Spark Post-Market Rally For T2 Biosystems (TTOO) Shares

    On Monday, T2 Biosystems, Inc. (NASDAQ: TTOO) shares experienced a significant increase on the US stock market following the post-market disclosure of its second-quarter 2024 results. In the extended trading session, TTOO stock value increased 22.78% to $5.82. That followed a regular-session fall of 6.88%, where shares finished at $4.74.

    How Well T2 Biosystems Performed?

    In line with the same time last year, T2 Biosystems (TTOO) reported total sales of $2.0 million. The T2Bacteria and T2Resistance panels had robust sales, which contributed to a notable 27% rise in the company’s sepsis test revenue. Remaining at $9.2 million, or $0.66 per share, was the quarter’s net loss; for the previous year, it was $6.3 million, or $7.84 per share.

    Strategic Initiatives and Expansion

    Looking ahead, T2 Biosystems anticipates further growth in sepsis-related revenue. This expectation is bolstered by the recent FDA clearance of an expanded T2Bacteria Panel, which now includes the detection of Acinetobacter baumannii. The company also foresees potential U.S. distribution partnerships with a major healthcare company and has recently secured international distribution agreements in five new countries.

    Additionally, the upcoming launch of the T2Lyme Panel as a Laboratory Developed Test (LDT) in the third quarter of 2024 presents another significant growth opportunity.

    International Expansion and Partnership

    T2 Biosystems announced separately that a territory-exclusive distribution arrangement for Indonesia and Malaysia had been signed. The T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel shall all be marketed by the recently designated distributor in accordance with this agreement.

    This agreement signifies continued momentum in T2 Biosystems’ international commercial expansion, particularly in the Asia Pacific region, following recent market entries in Hong Kong and Macau.

    One of the most important global health goals is to improve patient care for people who are at risk of sepsis. T2 Biosystems helps with this endeavor by offering culture-independent diagnostics to its distributor partners in Indonesia and Malaysia. The company’s footprint in the Asia Pacific region is further increased by the new distribution deal.

  • What Led The TTOO Stock To Increase In Premarket Session?

    What Led The TTOO Stock To Increase In Premarket Session?

    The share price of T2 Biosystems Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, was up 3.88% in pre-market trading at $1.07. Last session, TTOO closed at $1.03, losing -0.96% or $0.01. The price of each TTOO share fluctuated from $1.00 to $1.04 during the past session. A total of 3.2 million shares of TTOO stock were traded on the day, less than the company’s average daily volume of 4.66 million over the previous 50 days and a fraction of share volume of 8.17 million for the year to date.

    TTOO’s stock has suffered a decline of 39.59% in the past 12 months, and it has fallen -4.63% in the last week. TTOO stock has declined by -43.09% over the last six months, and by -12.71% over the last three months. Since the start of this year, the stock has lost -16.94%.  Following granting of the inducement award, TTOO stock is rising.

    Who is TTOO granting the award to?

    Using T2 Biosystems’ products, clinicians are able to effectively treat their patients faster than ever before, improving patient care and reducing costs. The T2Dx Instrument, T2Candida Panel, T2Bacteria Panel, T2Resistance Panel, and T2SARS-CoV-2 Panel available from TTOO are all powered by the T2MR (T2 Magnetic Resonance) technology. TTOO is developing future products such as the T2Cauris Panel, the T2Lyme Panel, and additional products to detect infectious pathogens that share antimicrobial resistance genes and biothreat pathogens.

    Eleven new employees received inducement awards from T2 Biosystems yesterday.

    • TTOO made the awards under its Inducement Award Plan on July 8, 2021.
    • On March 1, 2018, the program was adopted by TTOO, amended and restated on January 8, 2020.
    • Through TTOO’s Equity Incentive Program, new employees of the company are awarded equity awards.
    • As part of the inducement awards, employees received options to buy 321,000 shares of TTOO common stock, which were granted for a ten-year period.
    • On July 8, 2021, TTOO Biosystems common stock closed at $1.06 per share on the Nasdaq Capital Market, which was the exercise price of the options.
    • Over the next four years, employees’ options vest 25% on the first anniversary of their hire date, and the remainder vesting after that in equal monthly installments.

    How was the award granted?

    An independent compensation committee of the board of directors of TTOO approved the award. According to Nasdaq Marketplace Rules, the award was granted as an inducement material to entice the new employee to become employed by T2 Biosystems (TTOO).

  • 15 Trending Stocks To Watch In Diagnostics And Research Industry

    15 Trending Stocks To Watch In Diagnostics And Research Industry

    The Diagnostic Research Industry is playing an integral part in the medical evaluation and treatment of patients.  This industry is vital to the healthcare market as it is providing information related to the severity and causes of illnesses in patients to healthcare practitioners. The changes we are witnessing in today’s healthcare industry are setting the goal for evolution we will see over the next decade.

    There are major drivers that are changing and will change the direction of this industry in present and future as well. The first driver is technology. As time passes by, new technologies are emerging and playing a very important role in the healthcare industry. In today’s world, patients want easier access to care and demand better service. The demand for this industry is linked to the number of patients receiving the treatment. The profitability and growth of the company depend on good marketing and efficient operations.

    Let check these 15 companies in Diagnostic Research Industry to know more about this industry and the trends this industry is following:

    Interpace Biosciences Inc. (NASDAQ: IDXG)

    Interpace Biosciences Inc. (NASDAQ: IDXG) shares were trading up 32.89% at $3.96 at the time of writing on Wednesday. Interpace Biosciences Inc. (NASDAQ: IDXG) share price went from a low point around $2.57 to briefly over $11.00 in the past 52 weeks, though shares have since pulled back to $3.96. IDXG market cap has remained high, hitting $15.88M at the time of writing, giving it a price-to-sales ratio of more than 0.

    Interpace Biosciences Inc. (NASDAQ: IDXG) has announced that the Audit Committee has disclosed the result of an independent investigation. The committee has completed the investigation with the statement that the allegations made in the complaints were unverified and there is no truth behind them. investigation and If we look at the recent analyst rating IDXG, Janney initiated coverage on IDXG shares with a Buy rating.

    OPKO Health Inc. (NASDAQ: OPK)

    OPKO Health Inc. (NASDAQ: OPK) last closed at $4.07, in a 52-week range of $1.12 to $6.47. Analysts have a consensus price target of $8.00. OPKO Health Inc. (OPK) disclosed it plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020.

    Invitae Corporation (NYSE: NVTA)

    Invitae Corporation (NYSE: NVTA) stock drop by -6.29% to $49.28. The most recent rating by JP Morgan, on October 14, 2020, is at a Neutral. Invitae Corporation (NVTA) disclosed that on October 2, 2020, it has executed the transaction to bring ArcherDX into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization, and personalized cancer monitoring to enable precision approaches to cancer treatment.

    Pacific Biosciences of California Inc. (NASDAQ: PACB)

    Pacific Biosciences of California Inc. (NASDAQ: PACB) shares headed rising, higher as much as 0.07%. The most recent rating by JP Morgan, on October 02, 2020, is at an Overweight. Pacific Biosciences of California Inc. (PACB) has disclosed that collaborated with Children’s Mercy Kansas City to further understand the most challenging pediatric diseases. The companies will join forces to sequence a statistically significant cohort of rare disease cases for which previous whole-genome and whole-exome sequencing studies yielded no answers.

    Bionano Genomics Inc. (NASDAQ: BNGO)

    Bionano Genomics Inc. (NASDAQ: BNGO) fall -0.15% after losing more than $0.0 on Wednesday. Bionano Genomics Inc. (BNGO) revealed today that it is scheduled to release financial results of the third quarter ended September  30, 2020, on November 12, 2020. The company will also hold the conference call on the same day.

    T2 Biosystems Inc. (NASDAQ: TTOO)

    T2 Biosystems Inc. (NASDAQ: TTOO) stock drop by 0.00% to $1.33 after T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020. The most recent rating by BTIG Research, on October 08, 2020, is at a Buy.  T2 Biosystems Inc. (TTOO) market capitalization has remained high, hitting $196.79 million at the time of writing.

    NeoGenomics Inc. (NASDAQ: NEO)

    NeoGenomics Inc. (NASDAQ: NEO) Shares headed rising, higher as much as 5.46%. The most recent rating by Morgan Stanley, on September 09, 2020, is at an Overweight. NeoGenomics Inc. (NEO) revealed its plans to open a state-of-the-art research laboratory in China in association with the new lab PPD, Inc. (NASDAQ: PPD) is opening in Suzhou.

    PerkinElmer Inc. (NYSE: PKI)

    PerkinElmer Inc. (NYSE: PKI) fall -2.10% after losing more than -$2.62 on Wednesday. PerkinElmer Inc. (PKI) earlier announced that it is expected to report organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020.

    Chembio Diagnostics Inc. (NASDAQ: CEMI)

    Chembio Diagnostics Inc. (NASDAQ: CEMI) last closed at $4.77, in a 52-week range of $2.25 to $15.89. Analysts have a consensus price target of $5.00. Chembio Diagnostics Inc. (CEMI) disclosed earlier that the U.S. Food and Drug Administration (FDA) has approved the Premarket Approval (PMA) application for the DPP HIV-Syphilis System.

    Illumina Inc. (NASDAQ: ILMN)

    Illumina Inc. (NASDAQ: ILMN) Shares headed falling, lower as much as -4.35%. The most recent rating by Guggenheim, on October 13, 2020, is at a Neutral. Illumina Inc. (ILMN) has earlier announced that it is scheduled to release the third quarter 2020 following the close of the market on Thursday, October 29, 2020.

    Enzo Biochem Inc. (NYSE: ENZ)

    Enzo Biochem Inc. (NYSE: ENZ) fall -17.24% after losing more than -$0.45 on Wednesday. Enzo Biochem Inc. (ENZ) earlier reported financial results for the fourth quarter and full-year ended July 31, 2020, and provided a business update on recent corporate and operational developments.

    Fulgent Genetics Inc. (NASDAQ: FLGT)

    Fulgent Genetics Inc. (NASDAQ: FLGT) last closed at $38.17, in a 52-week range of $6.70 to $52.47. Analysts have a consensus price target of $56.25. Fulgent Genetics Inc. (FLGT) disclosed earlier that the Ohio Department of Rehabilitation and Correction (“ODRC”) has selected Fulgent Genetics for their COVID-19 testing needs.

    QIAGEN N.V. (NYSE: QGEN)

    QIAGEN N.V. (NYSE: QGEN) stock drop by -0.11% to $52.37. The most recent rating by BofA Securities, on October 06, 2020, is at a Buy. QIAGEN N.V. (QGEN) earlier announced preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020. It has shared that the Net sales grew 26% at actual rates, and also rose 26% at constant exchange rates (CER) $481.3 million from $382.7 million in the same period of 2019.

    Fluidigm Corporation (NASDAQ: FLDM)

    Fluidigm Corporation (NASDAQ: FLDM) last closed at $6.89, in a 52-week range of $1.17 to $12.45. Fluidigm Corporation (FLDM) has moved up 488.03% from its 52-weeks low and moved down -44.74% from its 52-weeks high. Looking at its liquidity, it has a current ratio of $509.65 million at the time of writing.

    Danaher Corporation (NYSE: DHR)

    Danaher Corporation (NYSE: DHR) stock soar by 0.41% to $226.55. The most recent rating by Wolfe Research, on June 16, 2020, is at an Outperform. Danaher Corporation (DHR) share price went from a low point around $119.60 to briefly over $227.48 in the past 52 weeks, though shares have since pulled back to $222.59. DHR  market cap has remained high, hitting $156.91 billion at the time of writing.